⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TARA News
Protara Therapeutics, Inc. Common Stock
Protara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral Support
globenewswire.com
TARA
Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
globenewswire.com
TARA
Focal Segmental Glomerulosclerosis (FSGS) Market Insights, Epidemiology and Forecast 2026-2036 - Targeted Therapies Reshape Treatment Through 2036
globenewswire.com
TARA
AMTX
AKBA
APLS
NVS
Form 8-K
sec.gov
TARA
Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
globenewswire.com
TARA
Alport Syndrome Market to Grow at a Tremendous 47% CAGR Through 2036, Driven by Emerging Therapies and Expanding Clinical Pipeline | DelveInsight
prnewswire.com
ELOX
EVTC
NVS
TARA
Form 8-K
sec.gov
TARA
Form 8-K
sec.gov
TARA
Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
globenewswire.com
TARA
Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026
globenewswire.com
TARA